Apta-1 has in the ongoing toxicology program indicated a good safety profile that resulted in a greater substance need, which delays the program
Aptahem AB (publ) announce today that the company's ongoing pre-clinical toxicology development program is delayed pending the manufacturing of more Apta-1. The drug candidate Apta-1 has in the company's ongoing toxicology program indicated a good safety profile, which has resulted in a greater substance need (Apta-1) than expected. The results also indicate that the dosages can be increased in the ongoing efficacy study in NHP (Non Human Primate), which warrant us to test higher dosages and lead to an extension of the study. The time required for the manufacturing of new substance causes